Charles River Q4 2023 revenue down 7.9% to $1.01B; non-GAAP EPS $2.46; 2024 guidance organic growth 0-3%

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

2023-FY EPS reported $9.22 revenue$4,129,409,000

Q4 GAAP EPS $3.62 vs $3.65 YoY; non-GAAP EPS $2.46 vs $2.98, down 17.4%.
Full-year 2023 revenue $4.13B (+3.9%); GAAP EPS $9.22; non-GAAP EPS $10.67.
2024 guidance: organic revenue growth 0%-3%; GAAP EPS $7.90-$8.40; non-GAAP EPS $10.90-$11.40.
Noveprim acquisition completed Nov 2023 (additional 41% stake for $144.6M, now 90% controlling interest).
DSA segment revenue fell 9.5% in Q4; Manufacturing organic growth +2.3% but revenue down 9.5%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported the fourth quarter ended December 30, 2023 results: revenue $1.01 billion, net income $187.1 million, EPS $3.62 per share.

Period: the fourth quarter ended December 30, 2023
Revenue: $1.01 billion
Net income: $187.1 million
EPS: $3.62 per share
Result: reported results

Exact text from the filing

EXHIBIT 99.1 Exhibit 99.1 Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance – Fourth-Quarter Revenue of $1.01 Billion and Full-Year Revenue of $4.13 Billion – – Fourth-Quarter GAAP Earnings per Share of $3.62 and Non-GAAP Earnings per Share of $2.46 – – Full-Year GAAP Earnings per Share of $9.22

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. updated its 2024 guidance (initiated).

Period: 2024
Guidance: initiated
Result: guidance update

Exact text from the filing

Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported the fiscal year ended December 30, 2023 results: revenue $4.13 billion, EPS $9.22 per share.

Period: the fiscal year ended December 30, 2023
Revenue: $4.13 billion
EPS: $9.22 per share
Result: reported results

Exact text from the filing

Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance – Fourth-Quarter Revenue of $1.01 Billion and Full-Year Revenue of $4.13 Billion – – Fourth-Quarter GAAP Earnings per Share of $3.62 and Non-GAAP Earnings per Share of $2.46 – – Full-Year GAAP Earnings per Share of $9.22 and Non-GAAP Earnings per Share of $10.67 – – Provides 2024 Guidance –

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. filing history →

Source: SEC EDGAR

accession 0001157523-24-000238

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.